attack in Biological Technology

Multiple Types of Heart Attacks Reduced by Prasugrel in TRITON-TIMI 38 Trial

... experienced reduced risk of heart attack regardless of heart-attack type (procedural ... analysis, the incidence of non-procedural heart attack in patients treated with prasugrel compared with ... Type 1: Spontaneous heart attack caused by a primary coronary event, such as a ...

VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients

... an acute coronary syndrome event such as a heart attack or unstable angina. The randomized, double blind, ... and major adverse cardiac events, such as heart attack and stroke. FDG-PET is a new and leading-edge ... and its complications, including heart attack and stroke. In addition, VIA's pipeline of drug ...

Heart Hospital of Austin First Site in World to Test Efficacy of New Adult Stem Cell Therapy to Treat Damaged Heart Tissue in Phase II Trial

... receives groundbreaking therapy days after heart attack AUSTIN, Texas, March 31 /PRNewswire/ -- ... and Drug Administration. After a Heart attack : In 2009 alone, more than half a million ... of men and 35% of women will have another heart attack within six years of their event. ...

BG Medicine Signs Collaborative Research Agreement with the National Heart, Lung and Blood Institute (NHLBI), and Boston University

... aims to identify those at high risk of heart attack and stroke, two of the world's leading killers. ... of cardiovascular disease or suffered a heart attack or stroke. Today, more than 9,000 participants ... of recognizing those at highest risk for heart attack or stroke. The HRP Initiative is supported and ...

MIT, BU team combats antibiotic resistance with engineered viruses

... bacteriophages (viruses that infect bacteria) to attack specific targets. "It's much easier to modify ... engineered viruses described in the PNAS paper attack the SOS system, a bacterial DNA repair system ... of a library of bacteriophages, each designed to attack different bacterial targets," said Lu. In ...

European Commission Approves EFIENT(R) (prasugrel) for Patients with Acute Coronary Syndrome Undergoing PCI

... endpoint of cardiovascular death, non-fatal heart attack or non-fatal stroke) in ACS patients undergoing ... patients who have had a prior transient ischemic attack (TIA) or stroke. Patients who weighed less than ... people in the United States annually.(2) Heart attack is a major manifestation of coronary heart ...

Synvista Therapeutics Announces Data Further Demonstrating the Value of Haptoglobin Genotyping in Diabetic Patients During AHA Meeting

... Diabetes may result in an increased risk of heart attack and rapid deterioration of HDL function. These ... were then followed for three years to track heart attack (myocardial infarction or MI), stroke and ... trials have demonstrated that the rate of heart attack in Hp2-2 diabetes can be decreased by the ...

Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units

... the use of early and rapid cooling in heart attack patients, which is being co-sponsored and ... who present within six hours of their heart attack and require angioplasty and stent procedures in ... tissue and cardiac function following a heart attack (acute myocardial infarction). Corgentin is a DNA ...

Synvista Therapeutics Announces Availability of Haptoglobin Genotyping Technology at The Annual Scientific Sessions of the American Heart Association

... control reduces the incidence of heart attack (myocardial infarction - MI) only in Hp2-2 ... and were followed for three years to track heart attack (myocardial infarction), stroke and death ... trials have demonstrated that the rate of heart attack in Hp2-2 diabetes can be decreased by the ...

Risky Business: New Survey Suggests Many Americans Live Dangerously, Even When They Say They Aren't 'Risk Takers'

... may help reduce the prevalence of heart attack and recurrent stroke, said the AMA. The new ... of aspirin for protecting against another heart attack (94 percent) or stroke (75 percent), and helping save your life if taken during a heart attack (82 percent). Among the group of patients ...

deCODE genetics Announces First Quarter 2008 Financial Results

... achieved positive clinical results for our heart attack and anti-platelet compounds DG051 and DG041, ... and human fertility and evolution. -- Heart attack - DG051. In January, the company announced ... is designed to counter risk of heart attack by reining in the activity of the leukotriene ...

Boston-Based BioDefense Corp. Announces New UK Partnership to Expand Markets for Biohazard Protection

... organizations from the threats of an actual attack or a disruptive hoax. The MailDefender(R) is ... needs to be developed." "A biological attack is likely to be far more devastating than the ... of people who were killed in the Twin Towers attack in New York City," said the Lord Guthrie. He went ...

Cardium's Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion

... and reperfusion model analogous to a heart attack or acute myocardial infarction, in which ... tissue and cardiac function following a heart attack and was conducted at Emory University ... tissue and cardiac function following a heart attack (acute myocardial infarction). Cardium believes ...

PCI Guideline Update Stresses Long-Term Anticoagulant Therapy After Treatment With Drug-Eluting Stents

... year, thousands of patients experiencing a heart attack or chest pain (known as angina) undergo ... artery who had suffered a heart attack between 72 hours and 28 days earlier but had ... patients to call 9-1-1 if they are having heart attack symptoms so they can get to the emergency ...

deCODE genetics Announces Third Quarter 2007 Financial Results

... double the risk of suffering an early heart attack -- before the age of 50 in men and 60 in women -- than are those who do not carry them. Heart attack remains the leading cause of death in the ... involved in conditions ranging from heart attack to cancer. We are turning these discoveries into ...

Monitoring water through a snake's eyes

... in using the technology. Skyscrapers in New York City a Likely Point of attack "Toxic materials are readily available as pesticides or herbicides in ... Prof. Aharon Katzir, was assassinated by the Japanese Red Army in a terror attack in 1972. "I am trying to walk in his footsteps by doing applied research ...

Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on GenSpera, Inc.

... directly. The Company's lead prodrug candidate, G-202, is designed to attack existing tumor vasculature, potentially debilitating the tumor's nutrient ... the Phase I trial. The Company's technology can also be used to attack cancer cells directly by targeting the prodrug to enzymes believed to be ...

Monitoring water through a snake's eyes

... in using the technology. Skyscrapers in New York City a Likely Point of attack "Toxic materials are readily available as pesticides or herbicides in ... Prof. Aharon Katzir, was assassinated by the Japanese Red Army in a terror attack in 1972. "I am trying to walk in his footsteps by doing applied research ...

The Crohn's & Colitis Foundation of America and Shire Launch Virtual 'IBD March on the Hill' to Increase Funding for Digestive Disease Research

... and ulcerative colitis are painful, medically incurable illnesses that attack the digestive system. Crohn's disease may attack anywhere from the mouth to the anus, while ulcerative colitis inflames ...

AstraZeneca Calls on All Americans to Join US AGAINST ATHERO to Fight the Nation's Number One Killer

... with a blood clot, memorably demonstrating how athero can lead to heart attack and stroke. "Now is the time to join us in the fight against this ... in the U.S.(3) Approximately 785,000 Americans will have their first heart attack in 2009 and about every minute someone will die from a coronary event.(2) ...

Alliance for Biosecurity Testifies Before Congress on Funding for Medical Countermeasure Development

... will not be developed and the nation will remain vulnerable to a bioterror attack - and make no mistake, a bioterror attack is a real and credible threat." New drug development is an ...

VIA Pharmaceuticals Announces Grant of New Patent on Lead Compound VIA-2291

... in combating cardiovascular disease and its complications, including heart attack and stroke. "Our clinical trial results presented at the most ... underlying cause of atherosclerosis and its complications, including heart attack and stroke. In addition, VIA's pipeline of drug candidates includes other ...

Multinational deCODE Study Identifies New Link Between Inflammation and Heart Attack

... that some of those variants were also risk factors for both heart attack and asthma. These discoveries may be used both in drug discovery and to ... on the study. The SNP on chromosome 12q24 associated with heart attack risk is in the SH2B3 gene (also known as LNK), which encodes the SH2B3 ...

BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis

... of multiple sclerosis (MS), an autoimmune disease caused by immune attack against normal components of the central nervous system. The sequence of ... or restoration of immunological tolerance with respect to ongoing immune attack as a result of high doses of peptide periodically delivered intravenously. ...

t2cure Acquires Patent Family on In Vitro Potency Testing of Stem Cells for Cardiovascular Application

... therapeutics a clinical reality for patients suffering from an acute heart attack or chronic heart failure." Each year, 40,000 patients are hit by a severe heart attack in Germany alone and many more are suffering from chronic heart disease. ...

Interleukin Genetics to Present New Findings at the 11th Cardiovascular Genomics and Atherosclerosis Symposium

... increase inflammatory responses and increase the risk for an early heart attack in Koreans. This information should be valuable in guiding the medical ... involved in inflammatory responses in individuals who had a heart attack or blocked coronary arteries prior to age 56. In addition, the study ...

VIA Pharmaceuticals to Host Investor Science Briefing on the Role of Inflammation in Cardiovascular Disease on Tuesday, September 16

... an underlying cause of atherosclerosis and complications such as heart attack and stroke." Dr. Libby is the Chief of Cardiovascular Medicine at the ... underlying cause of atherosclerosis and its complications, including heart attack and stroke. The company's lead drug candidate, VIA-2291, is in multiple ...

BioMS Medical's lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA

... of multiple sclerosis (MS), an autoimmune disease caused by immune attack against normal components of the central nervous system. The sequence of ... or restoration of immunological tolerance with respect to ongoing immune attack as a result of high doses of peptide periodically delivered intravenously. ...

BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis

... of multiple sclerosis (MS), an autoimmune disease caused by immune attack against normal components of the central nervous system. The sequence of ... or restoration of immunological tolerance with respect to ongoing immune attack as a result of high doses of peptide periodically delivered intravenously. ...

BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial

... of multiple sclerosis (MS), an autoimmune disease caused by immune attack against normal components of the central nervous system. The sequence of ... or restoration of immunological tolerance with respect to ongoing immune attack as a result of high doses of peptide delivered periodically by the ...

Expert Consensus Panel Recommendation for Incorporating Lp-PLA2 Testing into Cardiovascular Disease Risk Assessment Guidelines

... CVD risk to improve identification of those at even higher risk for heart attack and stroke who would benefit from proven therapeutic and lifestyle ... Lp-PLA2 can identify persons who are at increased risk for heart attack and/or stroke. Elevated Lp- PLA2 levels should prompt consideration of ...

Corgenix to Exhibit AspirinWorks(R) Test at ADA 2008 Meeting in San Francisco

... possible differences between healthy and diabetic men and women in heart attack and stroke risk reduction based on their response to the anti-clotting ... is important that individuals taking aspirin to lower the risk of a heart attack or stroke consult a physician to determine what dose, frequency and type ...

Ortho Evra Patch Makers Settling Cases

... about these risks. Evidence shows that the risk of blood clots, heart attack and stroke associated with Ortho Evra is significantly higher than with ... Ortho Evra Patch include: -- DVT (Deep Venous Thrombosis) -- Heart attack -- PE (Pulmonary Embolism) -- Stroke -- Blood Clots ...

Device That Clears Debris From Artery Aids Blood Flow in PCI

... the TAPAS study, which focused on patients suffering from a type of heart attack known as ST-elevation acute myocardial infarction (STEMI), are being ... blush grade and death, or a combination of death and repeat heart attack (p equals 0.001). The study team concluded that the degree of blood ...

The Lancet Publishes Results From World's First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent

... free at 1 year, n=29). MACE is a composite measure of cardiac death, heart attack and re-treatment of a diseased lesion (ischemia-driven target lesion ... as any event that resulted in re-treatment of a diseased artery, heart attack or cardiac death) and stent thrombosis (blood clot formation) rates -- at ...

Stonegate Report About Unigene Laboratories Inc.

... has reported a possible link between SERMs and increased risk of heart attack and stroke. Also, the FDA is currently seeking additional data to allow ... damage caused by cardiac reperfusion (rapid influx of blood) in heart attack and stroke patients, and the other is a combination therapy for the ...

deCODE Genetics Announces Full-year 2007 Financial Results

... MI(TM), a test for a major genetic risk factor for early-onset heart attack as well as abdominal aortic and intracranial aneurysms; deCODE ... discovered by deCODE chemists, is designed to counter risk of heart attack by reining in the activity of the leukotriene pathway, reducing the ...

Atherotech Says Detailed Cholesterol Test Can Help Doctors and Patients Choose Best Therapy

... lipoprotein patterns may be more important in decreasing the risk of heart attack and stroke than simply lowering LDL cholesterol alone. Unlike standard ... to determine the best therapy for reducing a patient's risk of heart attack and stroke. The VAP Test is available nationwide. About Atherotech, ...

Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.

... arteries, adversely affecting blood flow and increasing the risk of heart attack and stroke over time. The American Heart Association estimates that ... provide clinical benefits to patients by reducing the risk of heart attack and stroke. The niacin receptor, a G protein-coupled receptor, or GPCR, is ...

VIA Pharmaceuticals Expands Clinical Advisory Board With Leading Experts in Cardiovascular Disease

... the risk of major adverse cardiovascular events, including heart attack and stroke. According to the American Heart Association, 15.8 million ... underlying cause of atherosclerosis and its complications, including heart attack and stroke. The company's lead drug candidate, VIA-2291, is in multiple ...